with 9 of 27 (33%) treated with conventional combination been implicated in transfusion-associated hepatitis. The chemotherapy (P ! .036) despite similar transfusion historprevalence of HGV in a group of multitransfused patients ies. There was no significant difference in HGV positivity with hematological malignancy was studied using a reverse between patients treated before the introduction of United transcription polymerase chain reaction technique. TransfuKingdom blood donor screening for hepatitis C virus antision histories and serum aspartate aminotransferase (AST) body:18 of 39 (46%) and those treated after the introduction levels were recorded. HGV was detected in 29 of 60 (48%) of screening 11 of 21 (52%). HGV infection appears to be patients. There was no difference in HGV positivity rates extremely common in these patients; however, the clinical between those with normal AST levels and those with raised significance of these findings with respect to liver dysfunc-AST levels. Analysis of patients by treatment type showed tion is not yet clear. during their treatment for hematologic malignancy. Our aims
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Abbreviations: HGV, hepatitis G virus; AST, aspartate aminotransresults in both PCR reactions were considered HGV-PCR positive.
ferase.
No specimens gave indeterminate results, ie, positive in one PCR reaction only. Assays were validated by the inclusion of known positive and negative control samples. Precautions taken to avoid DNA contamination were those described by Kwok et al. positive group compared with the HGV-negative group was observed. There was no such trend with respect to number RESULTS of platelet units (Table 3 ). There was no significant differSixty patients were identified and studied (patient diagnoence in either the time from diagnosis or time from compleses are shown in Table 2 ). The patients were a mean of tion of treatment between the HGV-positive and HGV-nega-5.4 years from diagnosis and 4.1 years from completion of tive groups (Table 3) . Of the 11 patients who were still treatment. At the time of HGV testing, 11 patients were still receiving therapy, 4 were HGV positive. There was no sigreceiving treatment and 4 patients were in remission over nificant difference in time from diagnosis between the HGV-10 years since completion of therapy. A total of 29 patients positive and -negative patients in this subgroup. There were 15 patients with AST levels greater than 35 U/L (normal range, 4 to 30 U/L) at the time of HGV testing, and of these, 8 (53%) were HGV positive and 7 were HGV cordance between HGV and HCV within our population.
Median red blood cell units 27 30 .16
The mode or modes of HGV transmission to such a relatively screened for the parenterally transmitted viruses, human immunodeficiency virus 1 and 2, hepatitis B, and HCV. This raises the possibility that a nonparenteral route for HGV transmission may be involved. 33 (61%) patients who received a BMT were HGV positive compared with 9 of 27 (33%) who had been treated with Retrospective studies suggest that HGV RNA could persist for at least 4 years after infection.
3, 13 Our data show that conventional combination chemotherapy (x 2 Å 3.76, P Å .036). There was no significant difference between these two HGV may persist in patients for considerably longer; two patients were more than 9 years from the last possible transtreatment groups with respect to donor exposures, time from diagnosis, time from end of treatment, or changes in AST fusion exposure yet remained HGV-RNA positive. The patients in this study differ markedly from the UK level (Table 4) .
The data were assessed to see if there was a difference in hemophilia population studied by others, in which the reported prevalence of anti-HCV was 83%, almost all having prevalence of HGV between the cohort of patients who were treated and transfused before the introduction of donor detectable HCV RNA, but in which only 14% are HGV positive. 9 It is possible that the high rate of HGV positivity screening for HCV and the cohort who only received transfusions after this date. There was no significant difference in in our study may be related to immunosuppression at the time of exposure. This might increase the risk of infection HGV positivity between these two subgroups: 18 of 39 (46%) patients treated before HCV screening were HGV and persistence after exposure to HGV-positive blood products. The higher rate of HGV positivity in the more severely positive compared with 11 of 21 (52%) treated after screening.
immunocompromised BMT subgroup, despite similar levels of transfusion as non-BMT patients, supports this hypothesis. Although there was an apparent trend towards a lower HGV positivity rate with increasing time from diagnosis in Some patients who are HGV negative may have been inthose patients who had completed treatment, this was not statistically significant. The percentage of HGV-positive patients with respect to time from diagnosis is shown in Fig  1. No patients were on specific antiviral therapy at the time of HGV testing. During the course of treatment, all five of the patients with chronic myeloid leukemia had received therapy with a interferon, but this had been discontinued before BMT and exposure to blood components.
DISCUSSION
The finding that almost half of this multitransfused group of patients are positive by RT-PCR for HGV is further evidence that this virus is transmitted by blood transfusion. Linnen et al 3 indicated that the incidence of HGV in volunteer blood donors in the United States is around 1.6%. The 
